SPADA
Detection techniques for botulinum neurotoxins Limit of Detection Multiplex Format Sample‐Matrix Automation (ml ‐1 ) Interference
Method
1. Mouse Bioassay * 20 pg ELISA* 2.
No Limited No
Li it d M bl Li it d m e anagea e m e 3. ECL* 5 pg ‐50 ng Limited Manageable Limited 4. Lateral flow assay* 5‐50 ng No High N/A 5. Column flow assay* 1‐50 ng No High N/A 6. Flow cytometry assay 50 pg‐20 ng Yes Manageable Yes 7. Immuno‐PCR 1 pg‐ 5 pg Limited Manageable No 8. L‐PCR 0.02 fg Limited N/A No 9. BDG assay 100 ng Yes Low Yes 10. Array biosensor assay 40‐200 ng Yes Low Yes 11. Aptamer electrochemical assay 40 pg Yes Low Yes 12. Peptide array assay 3 pg Yes High Yes 13. ALISSA 0.5 fg No Low No 14. Endopep‐MS assay* 0.4 ‐6 pg Yes High Yes 15. Cell based assays 1‐10 ng No High No 5 pg ‐ 2 ng
(* assay used for food analysis); Enzyme-linked immunosorbent assay (ELISA); Electro-chemiluminiscent (ECL) assay; Liposomal-PCR (L-PCR): Bidiffractive grating (BDG) assay; Assay with a large immunosorbent surface area (ALISSA)
Fitness for Purpose To validate a rapid multi plex Clostridium botulinum - neurotoxin detection assay that has the ability to: • Detect and differentiate serotypes A through G • Detect bivalent toxins effectively and also determine the dominant type • Differentiate complex toxin with associated proteins from purified toxin (di-chain) and toxoid
10
Made with FlippingBook